Following the Government’s response to the Accelerated Access Review, the Accelerated Access Collaborative (AAC) has been established and is currently developing it’s working procedures. The AAC is selecting a small number of transformative products, likely between one and five, across medicines, devices, diagnostics and digital to begin working with to help speed up the formalisation of their processes.
Transformative products will likely be defined by the AAC in terms of both clinical features such as delivering major improvements to patient relevant outcomes and/or service delivery features such as net efficiency gains, cost savings or pathway re-engineering. However, the first selection of products the AAC intends to work with are those that have an established and mature evidence base and are already on the market in the UK. It will focus on transformative products where uptake and patient access is seen as challenging, despite positive NICE or other relevant guidance being in place. Following selections will consider products in earlier phases of development, clinical trials and those nearing licensing.
The nomination process closes on 09 March 2018.
If you would like to make a nomination for a transformative AAC product (or class of products), please complete the AAC Product Nomination Template and email it to Andrew Miniuks (firstname.lastname@example.org). Andrew Miniuks is also available to answer any questions you may have.
The Office for Life Sciences will be issuing further information about the AAC on their website.
To read more about the Government’s response to the Accelerated Access Review please click here.